Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Improving Muslim Women’s Uptake of Cancer Screening (IMCAN)

ABSTRACT: The goal of this non-randomised trial is to test how a workshop that includes religiously-tailored messages can help increase the uptake of breast, colorectal and cervical cancer screening among Muslim women in North East England and Scotland. The results of this trial will inform the development of a full-scale randomised-controlled trial. Participants in this study will be asked to take part in a two-hour workshop, deliver either online or in-person.

DISEASE(S): Bowel Cancer,Uterine Cervical Neoplasms,Cervical Cancer,Breast Cancer

PROVIDER: 115126 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

RNA-Seq of synovial tissue biopsies from individuals with rheumatoid arthritis from the R4RA randomised clinical trial

Project description:Transcriptomic profiles of synovial biopsies of rheumatoid arthritis (RA) patients who were recruited into the R4RA randomised clinical trial. Patients were randomised to treatment with rituximab or tocilizumab. All patients fulfilled the 2010 ACR/EULAR classification criteria for RA and were eligible for treatment with rituximab therapy according to UK NICE guidelines, i.e. failing or intolerant to csDMARD therapy and at least one biologic therapy (excluding trial IMPs) were recruited when fulfilling the trial inclusion/exclusion criteria. For the full study protocol and baseline patient characteristics see Humby et al (2021) The Lancet 397(10271): 305-17. PMID: 33485455.

2022-04-26 | E-MTAB-11611 | biostudies-arrayexpress

FinHER trial : Patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer

Project description:The FinHER trial is a multicentre phase 3 randomised adjuvant breast cancer trial that enrolled 1010 patients. The women were randomly assigned to receive three cycles of docetaxel or vinorelbine, followed by three cycles of fluorouracil, epirubicin, and cyclophosphamide.

2016-02-02 | GSE65095 | GEO

SRS endotype assignment of septic shock patients from the VANISH randomised trial

Project description:The aim of the experiment was to assign patients enrolled in the VANISH randomised trial to sepsis response signature (SRS) endotypes based on a previously published gene expression signature, in order to test for differential responses to treatment. VANISH was a double-blind randomised clinical trial in septic shock, with patients randomised to receive norepinephrine or vasopressin followed by hydrocortisone or placebo. We collected blood samples upon enrolment, extracted RNA and performed transcriptomic profiling using microarrays, allocated patients to SRS1 or SRS2 using a linear model (Davenport 2016), and tested for an association between sepsis endotype and response to either norepinephrine or vasopressin, or to corticosteroids. There was a significant interaction between treatment with hydrocortisone or placebo, and SRS endotype (p=0·02)

2022-07-12 | E-MTAB-7581 | biostudies-arrayexpress

Transcriptomic profiling of insecticide resistant field Anopheles funestus from Tanzania compared to a fully susceptible laboratory strain

Project description:Comparative gene expression profiling of Anopheles funestus insecticide resistant field strain from an area of a major insecticide treated bednet randomised control trial

2021-06-03 | E-MTAB-10579 | biostudies-arrayexpress

Transcriptomic profiling of insecticide resistant field Anopheles gambiae from Tanzania compared to fully susceptible laboratory strains

Project description:Comparative gene expression profiling of Anopheles gambiae insecticide resistant field strain from an area of a major insecticide treated bednet randomised control trial

2021-06-03 | E-MTAB-10580 | biostudies-arrayexpress

Matador,a multicenter clinical trial. Non-metastatic breast cancer patients were randomized between TAC or ddAC

Project description:Between 2004 and 2012, patients with pT1-3, pN0-3, M0 breast tumors were randomised between adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) versus docetaxel-doxorubicin-cyclophosphamide (TAC). Trial registration numbers: ISRCTN61893718 and BOOG 2004-04.

2021-12-30 | GSE167977 | GEO

Expression data from human peripheral B cells in hypoxic and normoxia

Project description:Human leukocyte cones were obtained from anonymous blood donors and peripheral blood B cells were isolated from PMBCs following ficoll density centrifugation. Isolated B cells were cultured in normoxia or 1% O2 for 24 h and RNA was extracted using an RNeasy Mini kit (Qiagen). This study was approved by the East of England - Cambridge Central Research Ethics Committee (REC reference 08/H0308/176).

2020-06-23 | GSE152960 | GEO

Steroid Pretreatment of Organ Donors to Prevent Postischemic Renal Allograft Failure: A Randomized, Controlled Trial

Project description:Comparison between pretreated donor grafts corticosteroid vs. placebo Prospective, randomised, double-blind, placebo-control trial, xls files contain normalized data (Default Total Intensity Normalization, see Stanford Microarray Database website), gpr files the raw data

2010-08-17 | E-GEOD-14700 | biostudies-arrayexpress

Respiratory Health Outcomes in Neonates (RHiNO) Study Urine Proteomics

Project description:Urine sampled from preterm-born (<34 weeks gestation) school-aged (7-12yrs) children and term born (>/=37 weeks gestation). Spirometry, exercise testing and cardiovascular assessment performed at time of sampling. Preter-born children with low lung function entered a randomised placebo controlled trial of inhaler therapies.

2023-07-31 | PXD042759 | Pride

Early life growth and gene profile changes during childhood

Project description:To compare early life exposures to see if they are associated with persistent molecular changes at the transcriptional level. Subjects were drawn from the Newcastle Pre-Term Birth Growth Study. A randomised, controlled trial to look at the effect on growth of dietary manipulation after hospital discharge.

2012-03-14 | GSE22013 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data